Concepedia
Statistics
Publications
144
Citations
10.7K
H-Index
48
Active since
1995
Affiliations
Rutgers Cancer Institute(Current)
Rutgers, The State University of New Jersey
Columbia University Irving Medical Center
City of Hope
National Cancer Institute
Mark N. Stein is an author at Rutgers Cancer Institute specializing in oncology, medicine, and pharmacology.
Publications per year
1995–2025
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher, Michael J. Morris, Walter M. Stadler et al. · Journal of Clinical Oncology · 2016 · 1.6K citations
Medicine, Oncology, Urology +17
A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors
Luis E. Raez, Kyriakos P. Papadopoulos, Alejandro D. Ricart et al. · Cancer Chemotherapy and Pharmacology · 2012 · 529 citations
Medicine, Oncology, Pharmacology +12
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg et al. · Journal of Clinical Oncology · 2012 · 458 citations · Full text
Medicine, Oncology, Pharmacology +17
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Janice M. Mehnert, Anshuman Panda, Kim M. Hirshfield et al. · Journal of Clinical Investigation · 2016 · 385 citations · Full text
Life Sciences, Immunology, Oncology +17
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H. O’Neil, John M. Wallmark, David Lorente et al. · PLoS ONE · 2017 · 305 citations · Full text
1–5 of 144